Is Moderna (MRNA) Stock Still Worth Buying After Its Huge Rally? JPMorgan Says Yes

Shares of vaccine maker Moderna (MRNA), a $26.5 billion company that lost half a billion dollars over the past year on sales of barely $50 million, are up more than four times from the $18-and-change price they sold for back at the beginning of the coronavirus crisis five months ago. And profits or no profits, they’re likely to go up a lot more today because of an announcement Moderna made after close of trading Tuesday.Releasing an “interim analysis” of the results from a Phase 1 study of its mRNA-1273 vaccine against COVID-19 Tuesday evening, Moderna confirmed that the results now …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.